U.S. License Holder:
Date of License:
ADMELOG (insulin lispro recombinant) is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In The E.U.
Admelog® (Sanofi) (July-2017)